QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.103.057489v1 307/3/1072    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takeshita, K. Articles by Gantner, F. Search for Related Content PubMed PubMed Citation Articles by Takeshita, K. Articles by Gantner, F.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Critical Role of Histamine H₄ Receptor in Leukotriene B₄ Production and Mast Cell-Dependent Neutrophil Recruitment Induced by Zymosan in Vivo

Bayer Yakuhin, Ltd., Research Center Kyoto, Respiratory Diseases Research, Kyoto, Japan

Received July 22, 2003; accepted August 26, 2003.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
The recently identified histamine receptor, H₄, was shown to be primarily expressed on leukocytes and has been implicated in the activation of lymphocytes, eosinophils, and mast cells in vitro. Its function in vivo, however, has not yet been characterized. We present evidence for a critical role of H₄ receptor in the mast cell-dependent recruitment of neutrophils. Mice injected with zymosan into the pleural cavity developed massive neutrophilia within hours after challenge. Neutrophilia was dose-dependently reduced when mice were pretreated with thioperamide, a known H_3/4 receptor antagonist, whereas H₁ and H₂ receptor antagonists lacked efficacy. Similarly, a 70 to 80% reduction in neutrophils in the pleural cavity compared with wild-type animals was noted in mice lacking mast cells (W/W^v mice); mice deficient in MyD88 (MyD88^–/–); a critical component of the signaling cascade of the major receptor for zymosan, toll-like receptor 2 (TLR2); or in mice pretreated with a functionally antagonistic anti-TLR2 antibody. The residual 20% neutrophil infiltration seen in mast cell-deficient and MyD88^–/– mice was not further reduced by thioperamide. Neutrophilia was completely restored by transferring wild-type bone marrow-derived mast cells into MyD88^–/– or W/W^v mice. Interestingly, when neutrophilia was evoked by carrageenan injection, mast cell depletion and thioperamide had no effect. Various inflammatory mediators were detectable in the pleural cavity of zymosan-challenged mice. Upon pretreatment with thioperamide, reduced levels of the neutrophil chemattractant leukotriene B₄ were observed, providing a mechanistic explanation for the prevention of neutrophilia by H₄ receptor antagonism.

Considerable expression of H₄ is also seen on lung tissue and lung cells (Coge et al., 2001; Morse et al., 2001; Zhu et al., 2001; Gantner et al., 2002), which makes H₄ receptor an attractive target for inflammatory lung disorders. Of particular interest is allergic asthma, where a causal role of mast cells, eosinophils, and lymphocytes is implied. Histamine itself, a long-known mediator of acute allergic reactions, has a variety of airway actions potentially relevant to the pathophysiology of asthma, such as airway smooth muscle contraction, vasodilation, the regulation of neurotransmitter release from airway nerve endings, and mucus production (Barnes et al., 1998). In addition, a plethora of different pro- and anti-inflammatory effects on immune cells are known for histamine (Jutel et al., 2002; Schneider et al., 2002), so its overall effect under chronic inflammatory conditions is hard to predict. However, recent evidence from mice carrying a disrupted gene for L-histidine carboxylase, thereby having much lower histamine tissue levels, suggests that the net effect of histamine in the allergic lung response is primarily in mediating eosinophilia but not hyperreactivity of the airways (Koarai et al., 2003). The relative histamine receptor contribution to this outcome, however, is still unknown.

Based on an overall homology of 37 to 43%, the human H₄ receptor is most closely related to H₃ receptor (Hough, 2001). This structural similarity is also reflected pharmacologically, as several compounds initially described as H₃ receptor-selective agonists or antagonists turned out to interact with H₄ receptor in a similar fashion. The apparent expression profile of H₃ and H₄ receptor, however, allows for the use of those pharmacological tools to investigate H₃ and H₄ receptor-mediated functions separately. In an attempt to elucidate the role of H₄ receptor in vivo, we studied two acute models of neutrophilia evoked by the inflammatory stimuli zymosan and carrageenan, respectively, and tested the H_3/4 receptor antagonist thioperamide for its potential modulation of neutrophil influx and mediator release. Experimental evidence for mast cell-driven, H₄ receptor-dependent leukotriene B₄ release and neutrophil recruitment is presented.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Chemicals. Histamine, thioperamide, pyrilamine, cimetidine, and zymosan were purchased from Sigma-Aldrich (St. Louis, MO). Carrageenan was purchased from Wako Pure Chemicals (Osaka, Japan). Fetal calf serum was obtained from JRH Biosciences (Lenexa, KS). RPMI 1640 medium was purchased from Invitrogen (Carlsbad, CA). Anti-TLR2 antibody and Ig-matched control antibody were purchased from eBioscience (#16-9021; San Diego, CA). Sodium azide was purchased from Nacalai Tesque (Kyoto, Japan). All bulk chemicals not further specified were purchased from Wako Pure Chemicals.

Mice. BALB/c and WBB6F1-W/W^v mice were purchased from Charles River Japan (Yokohama, Japan). MyD88^–/– mice (Adachi et al., 1998) were generated in the laboratory of S. Akira (Osaka University, Osaka, Japan).

Animals were kept under standard conditions in a 12-h day/night rhythm with free access to food and water ad libitum. All animals received humane care, and the studies were approved by the internal ethics committee in accordance with the guidelines recommended by the Japanese Association of Laboratory Animal Science.

Bone Marrow-Derived Mast Cell Cultures. Bone marrow-derived mast cells (BMMC) were generated from the femural bone marrow of 6- to 8-week old male mice and maintained in RPMI 1640 medium (Nacalai Tesque) supplemented with 10% fetal bovine serum (JRH Biosciences), 100 units/ml penicillin-streptomycin (Invitrogen), and 10 ng/ml recombinant murine IL-3 (PeproTech EC Ltd., London, UK) at a density of 1 x 10⁶ cells/ml. Prior to experimentation, BMMC were harvested, washed twice in PBS, and further used as indicated. Purity of mast cells was >95% as assessed by toluidine blue staining or fluorescence-activated cell sorting analysis of cell surface expression of c-kit and FcRI using specific antibodies (BD Biosciences Pharmingen, San Diego, CA and eBioscience).

Zymosan- and Carrageenan-Induced Pleurisy. Mice (BALB/c, Charles River Japan) received a single intrapleural injection with 0.2 ml of sterile saline containing -carrageenan (500 µg/mouse) or zymosan (100 µg/mouse) under anesthetization with ether. Test compounds [pyrilamine, cimetidine, thioperamide, dexamethasone, and vehicle (10% cremophor in PBS)] were administered p.o. (0.2 ml/head) 60 min prior to carrageenan injection. Four hours after injection, mice were euthanized, and pleural fluid was collected by washing the pleural cavity twice with 2 ml of PBS. The cell suspension was diluted to one-tenth in Turk's stain solution (Nacalai Tesque). The number of total cells in the sample was counted under the microscope using a hemocytometer. Cytospin specimens were stained with May-Gruenwald's (Merck, Darmstadt, Germany) and Giemsa's solution (Merck) for leukocyte typing. The distribution of each cell population (neutrophils, eosinophils, macrophages, lymphocytes, and others) was counted under microscopy by counting 200 to 300 cells.

Measurement of Soluble Mediators. Pleural fluid was collected by flushing the cavity with 2 ml of PBS. Samples were stored at –80°C until ELISA measurements according to the instructions of the manufacturer (KC, IL-6, TNF-, IL-1, IL-12p40, IL-4, interferon-, and granulocyte macrophage-colony stimulating factor were obtained from Genzyme-Techne, Minneapolis, MN, and LTB₄ was purchased from R&D systems, Minneapolis, MN).

Statistics. Data are expressed as means ± S.E.M. Statistical significance was determined using the unpaired Student's t test if applicable, or results were analyzed by using one-way ANOVA, and if variances were nonhomogeneous, differences between groups were assessed using Dunnett's method with commercially available statistic software (GraphPad Software Inc., San Diego, CA). P values <0.05 were considered statistically significant (, P < 0.05; , P < 0.01).

	Results

Top Abstract Materials and Methods Results Discussion References

 
Although zymosan-induced pleurisy is well established in the rat, the peritoneum is much more commonly used in the mouse to evoke a local inflammatory reaction by zymosan. To compare leukocyte recruitment evoked by zymosan and by carrageenan, another widely used trigger of neutrophilia, in the same body compartment, we first established a dose-response curve of zymosan and monitored the leukocyte influx into the pleural cavity of mice. As expected, massive cell infiltrates were found within 4 h after challenge in the pleural cavity, with neutrophils being the dominating population (80–90% of total cells). In parallel, activity of the neutrophil marker enzyme myeloperoxidase was detectable at time points greater than 2 h, peaked at 4 h, and remained elevated 24 h after zymosan injection (data not shown). The residual 10 to 20% of cells consisted of macrophages, eosinophils, mast cells, and a few lymphocytes, and the absolute numbers of these populations were comparable with those obtained from nonchallenged control mice. The dose-response relationship reached a maximum at 100 to 300 µg of zymosan per mouse. Neutrophilia evoked by a zymosan dose of 100 µg/mouse peaked at 4 to 6 h as shown in Fig. 1.

View larger version (40K): [in this window] [in a new window]   Fig. 1. Dose-response and time course of zymosan-induced neutrophilia in the pleural cavity of the mouse. Male BALB/c mice received zymosan by intrapleural injection (0.2 ml/cavity) at the doses indicated (A, B) or at 100 µg (C, D). Four hours later (A, B) or at the time points indicated (C, D), mice were euthanized, pleural fluid was collected, and the total cell and neutrophil numbers were microscopically determined. Data are expressed as mean values ± S.E.M. of six to eight animals per group. Results were analyzed using one-way ANOVA, and differences between groups were assessed using Dunnett's method (, P < 0.05; , P < 0.01).

Because mast cells and histamine have been shown to be critical for zymosan-induced inflammation in rodents (Tarayre et al., 1989; Kolaczkowska et al., 2001b; Kolaczkowska, 2002), we next evaluated their contribution to neutrophil influx into the pleural cavity. Mice pretreated with maximally tolerable doses of the histamine H₁ receptor antagonist, pyrilamine, or with the H₂ receptor antagonist, cimetidine, showed no change in the neutrophil influx. In contrast, pretreatment of mice with thioperamide, an H_3/4 antagonist, significantly reduced the inflammatory response in a dose-dependent manner (Fig. 2).

View larger version (21K): [in this window] [in a new window]   Fig. 2. Prevention of neutrophilia by the H4 antagonist thioperamide. Mice received various doses of the histamine receptor antagonists indicated or the corresponding volume of vehicle (V) i.v. (0.2 ml/head) 60 min prior to zymosan injection into the pleural cavity. Four hours later, mice were euthanized, pleural fluid was collected, and the number of neutrophils was microscopically determined. Data are expressed as mean values ± S.E.M. of six to eight animals per group. Results were analyzed using one-way ANOVA, and differences between groups were assessed using Dunnett's method (, P < 0.05; , P < 0.01).

W/W^v mice deficient in mast cells, the major cellular source of histamine, also showed an 80% reduction in neutrophilia upon zymosan challenge (Fig. 3A). Maximum efficacy was similar to that observed in thioperamide-treated mice, which prompted us to speculate that thioperamide might act on mast cell-expressed H₄ receptor (Morse et al., 2001; Gantner et al., 2002; Hofstra et al., 2003). In support of this hypothesis, no further reduction of neutrophilia was seen when thioperamide was given to mast cell-deficient animals (Fig. 3B). Neither mast cell nor H₄ receptor dependence was seen when neutrophil recruitment into the pleural cavity was evoked by carrageenan, i.e., neutrophilia was unchanged in W/W^v mice, and thioperamide pretreatment showed no effect either (Fig. 3, A and C).

View larger version (24K): [in this window] [in a new window]   Fig. 3. Mast cell dependence of zymosan- but not carrageenan-induced pleurisy. Mast cell-deficient W/Wv mice or wt control mice (+/+) were left untreated (nontreated, NT) or received an injection of carrageenan (500 µg/mouse) or zymosan (100 µg/mouse) into the pleural cavity (A). Various doses of the histamine receptor H4 antagonist thioperamide or the corresponding volume of vehicle (V) were given to W/Wv mice 60 min before zymosan challenge (B) or to wt mice prior to carrageenan injection (C). Four hours later, mice were euthanized, pleural fluid was collected, and the number of neutrophils was microscopically determined. Note the different scales of the y-axes. Data are expressed as mean values ± S.E.M. of six to eight animals per group. Statistical differences were analyzed using Student's t test where appropriate (A), or data were analyzed by one-way ANOVA, and differences between groups were assessed using Dunnett's method (B, C). , P < 0.01 versus +/+ control.

To further prove the mast cell dependence of the zymosan-induced reaction, we tested the neutrophil influx in mice lacking MyD88, a pivotal signaling module linked to toll-like receptors, including the mast cell-expressed zymosan receptor, TLR2. In accordance with our findings in mast cell-deficient mice, total cell influx (data not shown) and neutrophilia were dramatically reduced in zymosan-challenged MyD88^–/– mice (Fig. 4A). In addition, a similar reduction of neutrophilia was observed upon pretreatment of mice with an antibody directed against TLR2, whereas an Ig-matched control Ab was without effect (Fig. 4B). In line with our hypothesis, neutrophilia was inducible when W/W^v or MyD88^–/– mice were reconstituted with BMMC from wt or +/+ mice of the respective control strain, evidencing the necessity of zymosan-activated mast cells to recruit neutrophils (Fig. 4, C and D).

View larger version (27K): [in this window] [in a new window]   Fig. 4. Zymosan-induced MyD88 signaling via TLR2 is essential to evoke neutrophilia. MyD88–/–, wt mice (+/+), or wt mice pretreated by an anti-TLR2 Ab or a control Ab were challenged by zymosan, and neutrophils were counted 4 h later in the pleural cavity (A, B). W/Wv and MyD88–/– mice were reconstituted with 2 x 106 BMMC from wt (+/+) or MyD88–/– mice injected into the pleural cavity and challenged 1 week later by zymosan. Mice not transferred with BMMC (NT) served as controls (C, D). Dexamethasone or the corresponding volume of vehicle (V; 10% cremophor in PBS) was administered i.v. at the doses indicated 1 h before neutrophilia was induced in BALB/c mice by zymosan (100 µg/mouse; E) or carrageenan (500 µg/mouse; F). Data are expressed as mean values ± S.E.M. of six to eight animals per group. Statistical differences were analyzed by using one-way ANOVA, and differences between groups were assessed using Dunnett's method (, P < 0.05; , P < 0.01). Statistical differences were analyzed using Student's t test where appropriate (A-D), or data were analyzed by one-way ANOVA, and differences between groups were assessed using Dunnett's method (E, F). , P < 0.01; , P < 0.001 versus respective control group.

In contrast, carrageenan-induced neutrophilia remained unchanged in mice lacking MyD88 (data not shown). Dexamethasone, however, was similarly active in both models and reduced zymosan- and carrageenan-induced neutrophilia to a similar extent in a dose-dependent manner (Fig. 4, E and F).

To investigate the potential link between mast cell- and H₄ receptor-mediated neutrophil recruitment after zymosan stimulation, we looked for potential chemoattractant mediators being released into the pleural cavity of zymosan-challenged mice. Specifically, we collected pleural fluid within 1.5 h after challenge, i.e., before significant neutrophilia was observed. Increasing amounts of a variety of mast cell- or monocyte-derived factors, such as TNF-, IL-1, IL-6, IL-10, IL-12, KC, and LTB₄, were found over 90 min, whereas typical T cell cytokines, such as IL-4, IL-5, interferon-, or granulocyte macrophage-colony stimulating factor, were not detectable at any time point investigated (Fig. 5 and data not shown).

View larger version (19K): [in this window] [in a new window]   Fig. 5. Mediator release into the pleural cavity of zymosan-challenged mice. Mice were intrapleurally injected with zymosan (100 µg/mouse). At various time points after challenge, pleural fluid was collected by flushing the cavity with 2 ml of PBS. Samples were stored at –80°C until ELISA measurements. Data are expressed as mean values ± S.E.M. of six to eight animals per group.

We next investigated whether H₄ receptor might be involved in zymosan-induced mediator release in vivo and measured mediator concentrations in the pleural cavity of thioperamide-pretreated animals 90 min after challenge. A significant reduction in LTB₄ of about 75% was noted in H₄ receptor antagonist-treated animals compared with vehicle-treated controls. Likewise, LTB₄ levels were similarly reduced in mast cell-deficient mice (Fig. 6). A 20 to 30% reduction was also noted for KC (data not shown), whereas all other mediators remained unchanged upon thioperamide pretreatment.

View larger version (18K): [in this window] [in a new window]   Fig. 6. Reduced LTB4 levels in thioperamide-treated or mast cell-deficient mice. BALB/c mice received thioperamide (Thio; 30 mg/kg, i.v.) or the corresponding volume of vehicle (V; 10% cremophor) 1 h before intrapleural injection of zymosan (100 µg/mouse). W/Wv mice and their wild-type controls (wt) received the same dose of zymosan without any pretreatment. Ninety minutes after challenge, pleural fluid was collected by flushing the cavity with 2 ml of PBS. Samples were stored at –80°C until ELISA measurements. Data are expressed as mean values ± S.E.M. of 5 to 10 animals per group. Statistical differences were analyzed using Student's t test (, P < 0.01 versus vehicle or wt control, respectively).

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
The involvement of histamine and mast cells in the model of zymosan-induced peritonitis is well established. In the present report, we expand these findings to neutrophil recruitment into the pleural cavity and demonstrate that the recently identified receptor for histamine, H₄ receptor, is mediating this response.

Not surprisingly, the inflammatory response triggered by zymosan injection into the pleural cavity resembles the one observed in the peritoneum (Rao et al., 1994; Kolaczkowska et al., 2001a,b; Kolaczkowska, 2002). Neutrophils constitute the vast majority of all leukocytes recruited (cf. Fig. 1), mast cell deficiency diminishes (cf. Fig. 3A), whereas mast cell reconstitution in W/W^v mice restores neutrophilia (Fig. 4C), and a similar set of soluble mediators of inflammation are released within minutes and hours (cf. Fig. 5). Notably, the absolute number of mast cells recovered from the pleural cavity did not change upon zymosan challenge compared with naive animals (ca. 15,000 mast cells/cavity). This low number of mast cells apparently is still enough to control the recruitment of neutrophils upon zymosan challenge.

Caution has to be put on the interpretation of the pharmacological results obtained by the use of histamine receptor antagonists. We present here compelling evidence for H₄ receptor being critical for mast cell-dependent neutrophil recruitment. Thioperamide, a well characterized H₄ antagonist, but not antagonists specifically targeting H₁ or H₂ receptor, significantly reduced zymosan-induced neutrophilia. Although able to potently block H₃ receptors, thioperamide most likely acts on H₄ receptor expressed on mast cells that completely lack, as do most leukocytes studied so far, H₃ receptor. This conclusion is further supported by novel data obtained with the recently described H₃ receptor-inactive, H₄-selective antagonist JNJ 7777120, which showed identical efficacy in zymosan-induced mast cell-dependent neutrophilia in the mouse (oral presentation by Dr. R. Thurmond at the European Histamine Research Society meeting in Leiden, The Netherlands, May 2003; see patent WO 02072548 for details).

In contrast to our findings, partial inhibition of neutrophilia was reported in the zymosan-peritonitis model when mice were pretreated with H₁ receptor antagonists, such as mepyramine (Kolaczkowska et al., 2001b). This effect, however, was only seen at an early time point (2 h after challenge) but not 6 h after challenge, when neutrophilia was maximal, or thereafter. The major effect of H₁ receptor antagonists was seen on vascular permeability, a histamine effect known to be mediated primarily by H₁ receptor (reviewed in Hill et al., 1997), and thus, the diminished cell counts found in the peritoneum might be a consequence of such a response. Like thioperamide, mepyramine pretreatment had no effect on the levels of TNF- excluding reduced TNF levels as the mechanism leading to reduced neutrophilia after blockade of histamine action. In contrast, H₄ receptor antagonism clearly diminished the levels of LTB₄, one of the most potent chemoattractants known for neutrophils. This result fits well to the protective effect of leukotriene synthesis inhibitors (Rao et al., 1994) and the diminished zymosan response of mice lacking 5-lipoxygenase (Byrum et al., 1999) or the receptor for LTB4, BLTR (Haribabu et al., 2000). The fact that LTB₄ levels were also reduced in mast cell-deficient animals further supports the hypothesis of mast cell-expressed H₄ receptor as the primary target of thioperamide action. In line with this, we measured mediator release at 90 min after zymosan challenge, i.e., at a time point before neutrophils were recruited to the pleural cavity. This again argues for mast cells being the source of LTB₄ and the target of thioperamide action.

Of course, direct thioperamide effects on neutrophils cannot be fully excluded, although among murine leukocytes, only mast cells, eosinophils, and basophils have been reported to express H₄ receptor (Hofstra et al., 2003). Detailed analyses of H₄ receptor expression in mouse neutrophils isolated from various compartments and under various activation states are currently under investigation in our laboratory. All currently known functions of H₄ receptor are related to the control of leukocyte trafficking: histamine-induced chemotaxis of eosinophils (O'Reilly et al., 2002) and mast cells (Hofstra et al., 2003), the release of IL-16, a chemoattractant of CD4⁺ cells, from CD8⁺ lymphocytes (Gantner et al., 2002), and, finally, the zymosan-induced recruitment of neutrophils in vivo (this study).

Mechanistically, the neutrophil recruitment evoked by the two inflammatory stimuli, zymosan and carrageenan, fundamentally differs. Although both responses are sensitive to dexamethasone pretreatment (Fig. 4), the inflammatory response evoked by carrageenan obviously does not depend on H₄ receptor or mast cells (cf. Fig. 3, A and C), which is line with findings by others (Horakova et al., 1980; Lo et al., 1982; Damas and Remacle-Volon, 1986). Furthermore, preliminary studies reveal that the neutrophil populations infiltrating the pleural cavity seem to be recruited from different body compartments (data not shown). A more detailed analysis of the similarities and disparities underlying these two models is currently under investigation in our laboratory (unpublished data) and thus shall not be further discussed here.

Collectively, we describe here a role for the novel histamine H₄ receptor in vivo. We propose a model in which histamine, released from mast cells after TLR2-triggered MyD88 activation by zymosan, acts in an autocrine fashion on mast cell-expressed H₄ receptor, thereby leading to the release of chemoattractants for neutrophils among which LTB₄ has been identified as a likely candidate for mediating cell recruitment. The model of zymosan-induced pleurisy is a suitable model to selectively study the efficacy of H₄ receptor antagonists that might become future therapeutics to treat mast cell- and histamine-dependent disorders, such as allergy and asthma.

	Acknowledgements

 
We thank Prof. S. Akira (Osaka University, Japan) for kindly providing MyD88^–/– mice. Special thanks go to Dr. M. Shichijo for experimental advice.

	Footnotes

 
DOI: 10.1124/jpet.103.057489.

ABBREVIATIONS: IL, interleukin; BMMC, bone marrow-derived mast cells; KC, Kupffer cell-derived chemokine; LTB₄, leukotriene B₄; TLR2, toll-like receptor 2; PBS, phosphate-buffered saline; ELISA, enzyme-linked immunosorbent assay; TNF, tumor necrosis factor; ANOVA, analysis of variance; Ab, antibody; wt, wild-type.

Address correspondence to: Dr. F. Gantner, Bayer Yakuhin, Ltd., Research Center Kyoto, Respiratory Diseases Research, 6-5-1-3 Kunimidai, Kizu-cho, Soraku-gun, 619-0216 Kyoto, Japan. E-mail: florian.gantner.fg{at}bayer.co.jp

	References

Top Abstract Materials and Methods Results Discussion References

 

Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, and Akira S (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143–150.[CrossRef][Medline]

Bakker RA, Timmerman H, and Leurs R (2002) Histamine receptors: specific ligands, receptor biochemistry and signal transduction. Clin Allergy Immunol 17: 27–64.[Medline]

Barnes PJ, Chung KF, and Page CP (1998) Inflammatory mediators of asthma: an update. Pharmacol Rev 50: 515–596.[Abstract/Free Full Text]

Barocelli E and Ballabeni V (2003) Histamine in the control of gastric acid secretion: a topic review. Pharmacol Res 47: 299–304.[CrossRef][Medline]

Byrum RS, Goulet JL, Snouwaert JN, Griffiths RJ, and Koller BH (1999) Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 163: 6810–6819.[Abstract/Free Full Text]

Coge F, Guenin SP, Rique H, Boutin JA, and Galizzi JP (2001) Structure and expression of the human histamine H4-receptor gene. Biochem Biophys Res Commun 284: 301–309.[CrossRef][Medline]

Damas J and Remacle-Volon G (1986) Mast cell amines and the oedema induced by zymosan and carrageenans in rats. Eur J Pharmacol 121: 367–376.[CrossRef][Medline]

Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, and Bacon KB (2002) Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells. J Pharmacol Exp Ther 303: 300–307.[Abstract/Free Full Text]

Haribabu B, Verghese MW, Steeber DA, Sellars DD, Bock CB, and Snyderman R (2000) Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 192: 433–438.[Abstract/Free Full Text]

Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, and Haas HL (1997) International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49: 253–278.[Abstract/Free Full Text]

Hofstra CL, Desai PJ, Thurmond RL, and Fung-Leung WP (2003) Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 305: 1212–1221.[Abstract/Free Full Text]

Horakova Z, Bayer BM, Almeida AP, and Beaven MA (1980) Evidence that histamine does not participate in carrageenan-induced pleurisy in rat. Eur J Pharmacol 62: 17–25.[CrossRef][Medline]

Hough LB (2001) Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 59: 415–419.[Free Full Text]

Jutel M, Watanabe T, Akdis M, Blaser K, and Akdis CA (2002) Immune regulation by histamine. Curr Opin Immunol 14: 735–740.[CrossRef][Medline]

Koarai A, Ichinose M, Ishigaki-Suzuki S, Yamagata S, Sugiura H, Sakurai E, Makabe-Kobayashi Y, Kuramasu A, Watanabe T, Shirato K, et al. (2003) Disruption of L-histidine decarboxylase reduces airway eosinophilia but not hyperresponsiveness. Am J Respir Crit Care Med 167: 758–763.[Abstract/Free Full Text]

Kolaczkowska E (2002) Shedding light on vascular permeability during peritonitis: role of mast cell histamine versus macrophage cysteinyl leukotrienes. Inflamm Res 51: 519–521.[CrossRef][Medline]

Kolaczkowska E, Seljelid R, and Plytycz B (2001a) Critical role of mast cells in morphine-mediated impairment of zymosan-induced peritonitis in mice. Inflamm Res 50: 415–421.[CrossRef][Medline]

Kolaczkowska E, Seljelid R, and Plytycz B (2001b) Role of mast cells in zymosan-induced peritoneal inflammation in Balb/c and mast cell-deficient WBB6F1 mice. J Leukoc Biol 69: 33–42.[Abstract/Free Full Text]

Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J, Pyati J, Li X, Chai W, Carruthers N, et al. (2001) Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol 59: 420–426.[Abstract/Free Full Text]

Lo TN, Almeida AP, and Beaven MA (1982) Dextran and carrageenan evoke different inflammatory responses in rat with respect to composition of infiltrates and effect of indomethacin. J Pharmacol Exp Ther 221: 261–267.[Abstract/Free Full Text]

Morse KL, Behan J, Laz TM, West RE Jr, Greenfeder SA, Anthes JC, Umland S, Wan Y, Hipkin RW, Gonsiorek W, et al. (2001) Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 296: 1058–1066.[Abstract/Free Full Text]

Nakamura T, Itadani H, Hidaka Y, Ohta M, and Tanaka K (2000) Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 279: 615–620.[CrossRef][Medline]

Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, et al. (2001) Discovery of a novel member of the histamine receptor family. Mol Pharmacol 59: 427–433.[Abstract/Free Full Text]

Oda T, Morikawa N, Saito Y, Masuho Y, and Matsumoto S (2000) Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 275: 36781–36786.[Abstract/Free Full Text]

O'Reilly M, Alpert R, Jenkinson S, Gladue RP, Foo S, Trim S, Peter B, Trevethick M, and Fidock M (2002) Identification of a histamine H4 receptor on human eosinophil–role in eosinophil chemotaxis. J Recept Signal Transduct Res 22: 431–448.[CrossRef][Medline]

Rao TS, Currie JL, Shaffer AF, and Isakson PC (1994) In vivo characterization of zymosan-induced mouse peritoneal inflammation. J Pharmacol Exp Ther 269: 917–925.[Abstract/Free Full Text]

Repka-Ramirez MS and Baraniuk JN (2002) Histamine in health and disease. Clin Allergy Immunol 17: 1–25.[Medline]

Schneider E, Rolli-Derkinderen M, Arock M, and Dy M (2002) Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol 23: 255–263.[CrossRef][Medline]

Tarayre JP, Delhon A, Aliaga M, Barbara M, Bruniquel F, Caillol V, Puech L, Consul N, and Tisne-Versailles J (1989) Pharmacological studies on zymosan inflammation in rats and mice. 2: Zymosan-induced pleurisy in rats. Pharmacol Res 21: 385–395.[CrossRef][Medline]

Winbery SL and Lieberman PL (2002) Histamine and antihistamines in anaphylaxis. Clin Allergy Immunol 17: 287–317.[Medline]

Zhu Y, Michalovich D, Wu H, Tan KB, Dytko GM, Mannan IJ, Boyce R, Alston J, Tierney LA, Li X, et al. (2001) Cloning, expression and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 59: 434–441.[Abstract/Free Full Text]

This article has been cited by other articles:

				S. Zarini, M. A. Gijon, A. E. Ransome, R. C. Murphy, and A. Sala Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation PNAS, May 19, 2009; 106(20): 8296 - 8301. [Abstract] [Full Text] [PDF]

				T. L. Sutton, A. Zhao, K. B. Madden, J. E. Elfrey, B. A. Tuft, C. A. Sullivan, J. F. Urban Jr., and T. Shea-Donohue Anti-Inflammatory Mechanisms of Enteric Heligmosomoides polygyrus Infection against Trinitrobenzene Sulfonic Acid-Induced Colitis in a Murine Model Infect. Immun., October 1, 2008; 76(10): 4772 - 4782. [Abstract] [Full Text] [PDF]

				K.-i. Yuhki, F. Ushikubi, H. Naraba, A. Ueno, H. Kato, F. Kojima, S. Narumiya, Y. Sugimoto, M. Matsushita, and S. Oh-ishi Prostaglandin I2 Plays a Key Role in Zymosan-Induced Mouse Pleurisy J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 601 - 609. [Abstract] [Full Text] [PDF]

				M. M. Kelly, K. McNagny, D. L. Williams, N. van Rooijen, L. Maxwell, C. Gwozd, C. H. Mody, and P. Kubes The Lung Responds to Zymosan in a Unique Manner Independent of Toll-Like Receptors, Complement, and Dectin-1 Am. J. Respir. Cell Mol. Biol., February 1, 2008; 38(2): 227 - 238. [Abstract] [Full Text] [PDF]

				R. K. Morgan, B. McAllister, L. Cross, D. S. Green, H. Kornfeld, D. M. Center, and W. W. Cruikshank Histamine 4 Receptor Activation Induces Recruitment of FoxP3+ T Cells and Inhibits Allergic Asthma in a Murine Model J. Immunol., June 15, 2007; 178(12): 8081 - 8089. [Abstract] [Full Text] [PDF]

				R. M. van Rijn, P. L. Chazot, F. C. Shenton, K. Sansuk, R. A. Bakker, and R. Leurs Oligomerization of Recombinant and Endogenously Expressed Human Histamine H4 Receptors Mol. Pharmacol., August 1, 2006; 70(2): 604 - 615. [Abstract] [Full Text] [PDF]

				L E Sander, A Lorentz, G Sellge, M Coeffier, M Neipp, T Veres, T Frieling, P N Meier, M P Manns, and S C Bischoff Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract Gut, April 1, 2006; 55(4): 498 - 504. [Abstract] [Full Text] [PDF]

				J. F. Cailhier, D. A. Sawatzky, T. Kipari, K. Houlberg, D. Walbaum, S. Watson, R. A. Lang, S. Clay, D. Kluth, J. Savill, et al. Resident Pleural Macrophages Are Key Orchestrators of Neutrophil Recruitment in Pleural Inflammation Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 540 - 547. [Abstract] [Full Text] [PDF]

				H. D. Lim, R. M. van Rijn, P. Ling, R. A. Bakker, R. L. Thurmond, and R. Leurs Evaluation of Histamine H1-, H2-, and H3-Receptor Ligands at the Human Histamine H4 Receptor: Identification of 4-Methylhistamine as the First Potent and Selective H4 Receptor Agonist J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1310 - 1321. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.103.057489v1 307/3/1072    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takeshita, K. Articles by Gantner, F. Search for Related Content PubMed PubMed Citation Articles by Takeshita, K. Articles by Gantner, F.